Historically, disease research in neuroscience faced limitations due to species barriers and constraints with human samples. The advent of iPSC-induced neurons represents a significant breakthrough for academic and pharmaceutical research. Interdisciplinary collaborations have played a pivotal role in advancing iPSC technology. These collaborations have yielded innovative technologies, enhanced our understanding of cellular interactions and expanded iPSC applications. Despite progress, challenges persist, including concerns about tumorigenicity, immune rejection, inherent heterogeneity, and difficulty in recapitulating sporadic diseases. Scalability issues and the absence of age-associated cellular features in iPSC models are notable drawbacks. This concise review examines recent advancements in iPSC technology, focusing on its application in addressing neurological diseases. It delves into iPSC integration in the pharmaceutical industry, emphasizing roles in disease modelling, drug discovery, and screening. Looking ahead, the exploration of innovative strategies, interdisciplinary collaborations, and emerging technologies will continue shaping iPSC applications in neuroscience and the broader biomedical landscape. The systematic analysis and presentation of newly developed techniques in this review offer a roadmap for overcoming obstacles, emphasizing the transformative impact of iPSC technology on academic research and pharmaceutical development, and providing new avenues for understanding, treating, and potentially curing neurological diseases.
Select your language of interest to view the total content in your interested language